coat protein complex I subunit zeta 1Genealiases: CGI-120 · COPZ · HSPC181 · SCN12 · zeta-COP · zeta1-COP
Q-omics provides the consensus-scored COPZ1 profile across patient tissues and cancer cell-line models. COPZ1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COPZ1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, COPZ1 protein abundance shows 28,486 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where COPZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COPZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COPZ1 survival associations across molecular data types. COPZ1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COPZ1 RNA expression–survival associations across cancer types. High COPZ1 expression shows unfavorable associations in UVM, LIHC, BLCA, HNSC, ACC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COPZ1 RNA expression.
This table summarizes COPZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COPZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COPZ1 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, HNSC, LIHC and COAD. The KIRC box plot shows higher COPZ1 RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with COPZ1 in patient tissues and cancer cell lines. In patient samples, COPZ1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, COPZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
